...
首页> 外文期刊>EMBO Molecular Medicine >Gaining the hard yard: pre?¢????clinical evaluation of lentiviral?¢????mediated gene therapy for the treatment of ???2?¢????thalassemia
【24h】

Gaining the hard yard: pre?¢????clinical evaluation of lentiviral?¢????mediated gene therapy for the treatment of ???2?¢????thalassemia

机译:艰难的境地:慢病毒介导的基因疗法治疗2型地中海贫血的临床前评价

获取原文

摘要

Gene therapy is one potential novel therapeutic avenue for the treatment of inherited monogenic disorders. Diseases of the blood are frequent targets for gene therapy because it is relatively easy to harvest haematopoietic stem cells (HSCs) from the bone marrow, genetically modify the cells ex vivo , and then re?¢????administer the corrected cells back into the patient via intra?¢????venous injection. In this Closeup, Milsom and Williams discuss the work of Roselli et al, who describe the pre?¢????clinical evaluation of the treatment for ???2?¢????thalassemia in erythroid cells via the genetic correction of patient HSCs using a lentiviral vector. See related article in EMBO Mol Med (Roselli et al. (2010) EMBO Mol Med 2: 315?¢????328 )
机译:基因治疗是用于治疗遗传性单基因疾病的一种潜在的新型治疗途径。血液疾病是基因治疗的常见目标,因为从骨髓中收集造血干细胞(HSC)相对容易,离体对细胞进行遗传修饰,然后再将校正后的细胞重新施用于病人通过静脉注射。在本特写中,Milsom和Williams讨论了Roselli等人的工作,他们描述了通过红细胞遗传改造对红细胞中2型地中海贫血治疗的临床前评估。使用慢病毒载体的患者HSC。参见EMBO Mol Med中的相关文章(Roselli等人(2010)EMBO Mol Med 2:315 ??????? 328)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号